Motus GI Holdings (OTCPK:MOTS) - Aandelenkoers, Nieuws & Analyse

MOTS Overzicht aandelen

Motus GI Holdings, Inc. is actief als medisch technologiebedrijf in de Verenigde Staten.

MOTS fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 8.2% per jaar gegroeid

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $7K )

Heeft een omzet van minder dan 1 miljoen USD ( $327K )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Motus GI Holdings, Inc. Concurrenten

ViewRay

OTCPK:VRAY.Q

US$18.3k

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Wearable Health Solutions

OTCPK:WHSI

US$1.8k

ThermoGenesis Holdings

OTCPK:THMO

US$9.5k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Motus GI Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$0.001
52 Week Hoogtepunt	US$5.75
52 Week Laag	US$0.001
Bèta	1.81
11 maand verandering	-97.50%
3 maanden verandering	-98.17%
1 Jaar Verandering	-99.98%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Motus GI regains compliance with minimum bid price requirement

Aug 11

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Jul 25

Motus GI starts enrollment in Pure-Vu System EU study

Jun 16

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System

Apr 30

Here's Why Motus GI Holdings (NASDAQ:MOTS) Can Manage Its Debt Despite Losing Money

Mar 02

Rendement voor aandeelhouders

	MOTS	US Medical Equipment	US Markt
7D	-33.3%	0.2%	-1.3%
1Y	-100.0%	25.6%	30.7%

Rendement versus industrie: MOTS presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 25.6 % opleverde.

Rendement versus markt: MOTS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.7 % opleverde.

Prijsvolatiliteit

Is MOTS's price volatile compared to industry and market?
MOTS volatility
MOTS Average Weekly Movement	45.2%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van MOTS is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 45% ) van MOTS is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	15	n/a	www.motusgi.com

Motus GI Holdings, Inc. is een medisch-technologisch bedrijf in de Verenigde Staten. Het ontwikkelt het Pure-Vu systeem, een medisch hulpmiddel om het reinigen van een slecht voorbereid maagdarmkanaal tijdens de colonoscopie te vergemakkelijken en vergemakkelijkt procedures voor endoscopie van het bovenste deel van het maagdarmkanaal. Het bedrijf was voorheen bekend als Eight-Ten Merger Corp. en veranderde zijn naam in Motus GI Holdings, Inc. in november 2016.

Motus GI Holdings, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Motus GI Holdings zich tot de beurswaarde?
MOTS fundamentele statistieken
Marktkapitalisatie	US$7.19k
Inkomsten(TTM)	-US$16.10m
Inkomsten(TTM)	US$327.00k

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is MOTS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MOTS resultatenrekening (TTM)
Inkomsten	US$327.00k
Kosten van inkomsten	US$407.00k
Brutowinst	-US$80.00k
Overige uitgaven	US$16.02m
Inkomsten	-US$16.10m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.24
Brutomarge	-24.46%
Nettowinstmarge	-4,924.16%
Schuld/Eigen Vermogen Verhouding	75.0%

Hoe presteerde MOTS op de lange termijn?

Bekijk historische prestaties en vergelijking

MOTS Overzicht aandelen

Beloningen

Risicoanalyse

Motus GI Holdings, Inc. Concurrenten

OTCPK:VRAY.Q

US$18.3k

OTCPK:LHDX.Q

US$4.2k

OTCPK:WHSI

US$1.8k

OTCPK:THMO

US$9.5k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Motus GI Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $4.99972 million.

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Motus GI Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $4.99972 million.

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

New minor risk - Share price stability

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$2.48 loss

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

Price target increased by 58% to US$10.00

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI regains compliance with minimum bid price requirement

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Price target decreased to US$1.43

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Price target decreased to US$1.73

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Price target decreased to US$1.86

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company